Gaviscon and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gaviscon (aluminum hydroxide; magnesium trisilicate) and Ibrance (palbociclib). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Gaviscon and Ibrance. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Gaviscon?

Gaviscon has active ingredients of aluminum hydroxide; magnesium trisilicate. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 12,355 Gaviscon users. Check the latest studies of Gaviscon.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

21 people who take Gaviscon and Ibrance together, and have interactions are studied.

What are the common drug interactions of Gaviscon and Ibrance, by gender? *:

female:

Fatigue (feeling of tiredness)
Neuropathy peripheral (surface nerve damage)
Constipation
Full blood count decreased
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Abdominal pain upper
Anaemia (lack of blood)
Back pain
General physical health deterioration (weak health status)

male:

n/a

What are the common drug interactions of Gaviscon and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Body height decreased
Bone disorder
Bone pain
Breast cancer recurrent
Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)
Coronary arterial stent insertion
Cystitis (inflammation of the wall of the bladder)
Drug ineffective
Gastric neoplasm (a tumour that develops in the stomach)
Injection site pain

60+:

Fatigue (feeling of tiredness)
Neuropathy peripheral (surface nerve damage)
Constipation
Full blood count decreased
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Abdominal pain upper
Anaemia (lack of blood)
Back pain
General physical health deterioration (weak health status)

What are the existing conditions these people have? *

Breast Cancer Female: 9 people, 42.86%
Breast Cancer: 6 people, 28.57%
Pain: 4 people, 19.05%
Breast Cancer Metastatic: 4 people, 19.05%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 14.29%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 14.29%
High Blood Pressure: 3 people, 14.29%
Diarrhea: 3 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Gaviscon and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously